Condition
Lung Cancer - Non Small Cell Squamous
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07353957Phase 2RecruitingPrimary
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
NCT07459283Early Phase 1Not Yet Recruiting
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
NCT07127263CompletedPrimary
Comparison of Longer-term (5 Year+) Outcomes (Survival) of Smokers, Ex-smokers, Never Smoker and Quitters
NCT01285609Phase 3CompletedPrimary
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
Showing all 4 trials